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Background: The resectability of colorectal liver metastases is in part largely based on the surgeon's
assessment of cross-sectional imaging. This process, while guided by principles, is subjective. The
objective of the present study was to assess agreement between hepatic surgeons regarding the
resectability of colorectal liver metastases.
Methods: Forty-six hepatic surgeons across Canada were invited. A patient with biologically favourable
disease was presented after having received neoadjuvant chemotherapy. The scenario was matched with
10 different scrollable abdominal CT scans representing a maximum response after six cycles of che-
motherapy. Surgeons were asked to offer an opinion on resectability of liver metastases, and whether they
would use adjunct modalities to hepatic resection.
Results: Twenty-six surgeons participated. Twenty responses were complete. The median number of
scenarios deemed resectable was 6/10 (range 3–8). Two control scenarios demonstrated perfect agree-
ment. Agreement on resectability was poor for 4/8 test scenarios, of which one scenario demonstrated
complete disagreement. Among resectable cases, the pattern of use of adjunct modalities was variable.
A median ratio of 0.87 adjunct modality per resectable scenario per surgeon was used (range 0.25–1.75).
Conclusion: A significant lack of agreement was identified among surgeons on the resectability and use
of adjunct modalities in the treatment of colorectal liver metastases.
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Introduction
Colorectal cancer is the third most commonly diagnosed cancer in
North America, and the second leading cause of cancer-related
death.1 Approximately 50% of patients diagnosed with colorectal
cancer will develop liver metastases during the course of their
disease.2 For patients with metastatic colorectal cancer isolated in
the liver, the cornerstone of therapy is complete surgical resection.
The addition of modern chemotherapy to surgery has resulted in
5-year survival rates of 37–58% and 10-year survival rates of
16–30%.3–7
All patients with isolated colorectal liver metastases should be
evaluated for liver resection. In the absence of contraindications,
the resectability of colorectal liver metastases is in part largely
based on the surgeon’s assesment of cross-sectional imaging. It is
the authors’ hypothesis that a significant element of subjectivity
influences the determination of resectability. There is currently a
paucity of literature addressing the subjectivity of this process, as
well as the variability among surgeons. In this context, the objec-
tive of the present study was to assess agreement between hepatic
surgeons regarding the resectability of colorectal liver metastases.
A further aim of the study was to evaluate patterns of use of
adjunct modalities to resection among hepatic surgeons.
Podium presentation at the 9th World Congress of the International
Hepato-Pancreato-Biliary Association, April 2010, Buenos Aires, Argentina.
DOI:10.1111/j.1477-2574.2012.00440.x HPB
HPB 2012, 14, 291–297 © 2012 International Hepato-Pancreato-Biliary Association
Materials and methods
After obtaining approval from the Ottawa Hospital Research
Ethics Board, hepatic and/or transplant surgeons across Canada
were identified through website listings of all university health
centres. All hepatic surgeons were invited to participate via email,
which included a brief description of the study and its aims. Each
surgeon was issued with a unique invitation link. This was done to
prevent duplicate answers from the same surgeon. Reminders
were sent to surgeons who had not completed the survey.
An email invitation was sent to 46 surgeons. One invitation was
not delivered as the email address was not accurate and no alter-
native email could be identified. Two surgeons replied and stated
that they only perform pancreatic surgeries. Forty-three hepatic
surgeons were thus considered to have been invited to participate.
The survey consisted of questions pertaining to 10 patients with
a standardized clinical scenario. All scenarios were presented with
the same clinical history: a young healthy patient with node nega-
tive primary colorectal cancer [T3, N0 (0/17)] and a metachro-
nous liver lesion(s) detected at follow-up 4 years after treatment of
the primary. The scenarios indicated that the patients were
restaged and had no other significant findings. All patients were
assumed to have received six cycles of modern neoadjuvant
chemotherapy, in order to accommodate for the concept of
downstaging.
For each scenario, a scrollable post-treatment computed
tomography (CT) scan was presented, representing the extent of
disease after six cycles of treatment. Only one phase of a tri-phasic
CT scan was shown. This phase represented the best image
sequence for a particular patient, and surgeons were informed
that no other lesion could be seen on the other CT phases. Only
cuts of the liver were shown, as extra-hepatic disease was pre-
sumed to be absent.
For 9 out of 10 patients, the post-treatment CT scan was
reported to be unchanged from the pre-treatment CT. For the last
patient, both pre- and post-treatment CT scans were shown. This
patient had a dramatic response with some lesions disappearing
with the neoadjuvant chemotherapy treatment.
The 10 CT scans represented a variety of clinical presentations
of colorectal liver metastases (Fig. 1). Those included single vs.
multiple lesions, bilobar disease, lesions in proximity to major
vascular structures or ‘ill-located’ lesions, disease where a resec-
tion could leave a small future liver remnant, as well as disappear-
ing lesions. Two of the CT scans were included as controls. The
first control scan showed a single peripheral lesion, whereas the
second represented a liver overburdened with numerous bi-lobar
metastases. Those were presumed to be easily recognizable by an
expert as resectable and non-resectable disease, respectively. Both
control scenarios were embedded within the series of test sce-
narios and were not labelled as controls.
The surveyed surgeons were asked to decide on the best man-
agement for the patient based on the CT scan images. Two options
were presented: ‘(i) resection  adjuncts to resection’, or (ii) ‘this
patient is unresectable’. Once the patient was deemed resectable,
the surgeons were asked to indicate which adjunct modalities they
would plan to use in this case, if any. Available options included
radiofrequency ablation (RFA), portal vein embolization (PVE)
and a staged hepatectomy. The surgeons could refrain from using
these adjunct modalities or could choose one or more option. All
surgeons were assumed to have sufficient experience with hepatic
surgery and access to modern technologies to be able to render
an informed opinion on resectability and the use of adjunct
modalities.
At the end of the clinical scenarios, demographical questions
were included to further define the participating population of
surgeons. Surgeons were asked about their current practices in
term of HPB surgery, liver transplant surgery or both. The prac-
tice setting was identified in relation to academic (transplant/
non-transplant) centres vs. community hospitals. The number of
HPB/transplant surgeons, years in practice and the percentage of
HPB/transplant surgery in the surgeon’s practice were all sur-
veyed. It was also established whether the surgeons were currently
involved in the treatment of patients with colorectal liver
metastases. Finally participants were asked to provide a short
description of their definition of resectability.
A website was created to host the survey. Internet access was
required for participation. All survey questions were presented
sequentially, and upon completion of a question, the next one was
presented. Participants were allowed to go back and change their
answers provided that this was done before completion of the
survey. An option to save a partially completed survey was also
offered, allowing completion at a later time.
All survey data were extracted and analysed using Microsoft
Excel (Microsoft Corporation, Richmond, WA, USA). Agreement
among surgeons on resectability was presented as proportions
of respondents indicating that a given patient had resectable or
unresectable disease. Perfect agreement was achieved when all
surgeons agreed on resectability or unresectability. Complete
disagreement was identified when exactly half of the surgeons
chose resectability and half chose unresectability, as would be
expected by chance alone. For all cases deemed resectable, the total
number of adjunct modalities utilized was calculated per surgeon.
In order to account for the different number of scenarios identi-
fied as resectable by different surgeons, the total number of
adjunct modalities used was standardized against the number
resectable scenarios for a given surgeon. These data were thus
expressed as a ratio of the number of adjunct modalities used per
resectable scenario per surgeon. All continuous variables were
presented as medians and range. All dichotomous variables were
expressed as proportions or percentages. Medians were compared
using Wilcoxon’s rank-sum tests.
Results
A total of 26 out of 43 responses were received: 20 of those were
complete and 6 responses were partial. All participants were
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attending surgeons and all but one, practiced at academic institu-
tions. Twelve out of 20 participants were also liver transplant
surgeons.
At the time of response, 12 participants had been in practice for
at least 5 years. Ten of the participants worked in groups of 3 to 5
surgeons, and HPB surgery represented more than 50% of the
workload for 18 participating surgeons. All but one of the partici-
pants stated that they were actively involved in the treatment of
patients with colorectal liver metastases.
The two control scenarios demonstrated perfect agreement. All
20 surveyed surgeons elected to resect the first control scenario,
which represented a single peripherally located metastasis. The
second control scenario represented a liver overburdened with
multiple, bilateral metastases affecting almost all hepatic seg-
ments. None of the participating surgeons offered a liver resection
and all 20 agreed on the fact that this disease was unresectable.
The median number of test scenarios deemed resectable per
surgeon was 6 (range 3–8). Agreement on resectability among
surgeons was highly variable (Fig. 2). A significant lack of agree-
ment was demonstrated for 4/8 test scenarios (scenarios 5, 6, 8,
and 9), with scenario 9 exhibiting complete disagreement. Outside
of the control scenarios, only one scenario achieved perfect agree-
ment for resection (scenario 3). The remaining three test scenarios
demonstrated good agreement, each with over 17 surgeons con-
curring on resectability.
Surgeons involved in both HPB and transplant surgery were
more likely to find patients resectable than surgeons solely prac-
ticing HPB surgery [median resectable scenarios 7 (interquartile
range 6–7) vs. 5 (4.5–6.5), P = 0.14]. No difference was identified
between surgeons with less than 5 years of experience and those
with 5 or more [median 6.5 (5–7) vs. 6 (5–7), P = 0.97].
For scenarios considered resectable, the pattern of use of
adjunct modalities was variable among participating surgeons
(Fig. 3). From the pool of 10 survey scenarios, the median number
of adjunct modalities used per surgeon was 5 (range 1–14). The
median ratio of adjunct modalities used per resectable scenario
per surgeon was 0.87 (range 0.25–1.75). The type of adjunct
modalities used was also variable between surgeons (data not
shown).
In defining resectability of colorectal liver metastases, 13 sur-
veyed surgeons provided a definition consistent with a recently
published Expert Consensus Statement.8 Other descriptors used
included the ability to obtain a 1 cm margin, biological behaviour
of the disease, resection based on only pre-chemotherapy imaging
and resection of all known ghost lesions if feasible. Two surgeons
did not provide a definition, and stated that there is ‘no single
definition’.
Discussion
The present study has addressed the resectability of colorectal liver
metastases. To the authors’ knowledge, this is one of the first
studies to specifically describe the variablility associated with this
process within a group of hepatic surgeons. The current work is
unique in that clinical experts in liver surgery were asked to
provide an opinion regarding individual cases based on cross-
sectional imaging, assuming ideal oncological parameters. In spite
of widely agreed upon modern principles of resectability,8 this
study has demonstrated a significant lack of agreement for at least
50% of test scenarios, in addition to tremendous variability in the
use of adjunct treatment modalities.
The present study was specifically designed to assess surgeon
opinions on technical resectability based on cross-sectional
imaging. However, a multitude of other tangible and intangible
factors affect whether a patient will undergo curative liver resec-
tion, including comorbidities, performance status, tumour
biology, response to chemotherapy, the choice of pre-operative
staging imaging, presentation at multidisciplinary conferences
and local experience with liver surgery. That being said, it can be
argued that resectability most frequently boils down to surgical
Figure 2 Agreement on resectability per scenario
294 HPB
HPB 2012, 14, 291–297 © 2012 International Hepato-Pancreato-Biliary Association
judgement guided by the examination of CT scans and/or mag-
netic resonance imaging. In order to study this complex process,
the present study attempted to control for all other clinical vari-
ables that commonly influence such decisions, by proposing a
hypothetical healthy patient with favourable disease biology.
Although this approach is artificial, the authors argue that it was
the most methodologically-sound means to study the given ques-
tion, without introducing further bias based on additional clinical
data.
The criteria for resectability of colorectal liver metastases have
evolved over time, and continue to be liberalized.2,8–11 Today, resec-
tion principles are based on the remnant liver, with preservation
of adequate vascular inflow, outflow and biliary drainage. Current
literature advocates that at least two adjacent liver segments
should be spared, and the resection should result in macroscopic
and microscopic elimination of the disease.12 A sufficient future
remnant liver volume is a critical pre-requisite (>20%), with
remnant volume requirements increasing in the context of liver
injury from chemotherapy, steatosis or hepatitis (30–60%), as well
as in the presence of cirrhosis (40–70%). Contraindications to
liver resection would include uncontrollable extrahepatic disease
such as a non-treatable primary tumour, widespread pulmonary
disease, peritoneal disease, extensive nodal disease, such as retro-
peritoneal or mediastinal nodes and bone or CNS metastases.13
These principles have been formalized in the published recom-
mendations of a 2006 consensus conference.8 Data from the
present study would indicate that a majority of practicing hepatic
surgeons in Canada are familiar with these principles, as evi-
denced by definitions provided by survey respondents.
In spite of the above-mentioned principles of resectability, this
study has demonstrated that surgeons sometimes arrived at dif-
ferent conclusions based on the same clinical data. Moreover, even
in patients deemed resectable, surgeons often opted to use a
widely different array of treatment modalities to achieve a pre-
sumed similar clinical outcome. These findings highlight the
importance of decision-making processes in modern surgical
practice.14 Using this premise, it can be inferred that decisions on
resectability are influenced by individual surgeon factors such
practice patterns, individual biases and experiences, comfort levels
with risk, and interpretation of the literature. This interpretation
is further supported by the fact that patient-level factors were at
least partially controlled for by our use of a standardized clinical
scenario.
Pre-operative imaging plays a pivotal role in the evaluation of
patients with colorectal liver metastases. It facilitates surgical plan-
ning by defining the extent and distribution of hepatic metastases,
as well as by identifying extra-hepatic disease.8 Currently,
contrast-enhanced CT is the preferred modality in the assessment
of colorectal liver metastases. Most comparative studies have
shown that MRI is not superior to CT in this context.15,16 As such,
the technical aspect of resectability is highly dependent on the
interpretation of the cross-sectional imaging, as highlighted in the
present study. The onus is on the surgeon to identify and properly
select patients who are candidates for liver resection in the pres-
ence of colorectal liver metastases. The impact of this process on
the patient population is significant, as denial of a liver resection
will significantly influence outcomes with important implications
for quality of life and overall prognosis.3–7,17–19 In contrast, offering
a liver resection when not indicated exposes the patient to signifi-
cant risk with questionable benefits. As such, the current work
would support a definition of resectability that is not based on
individual surgeons’ opinions, but rather on consensus opinions
generated by multidisciplinary conferences or ‘tumour boards’.
This belief is supported by literature demonstrating that patients
with metastatic colorectal cancer assessed at such conferences are
more likely to undergo hepatic metastatectomy.20
The lack of agreement on resectability and the use of adjunct
modalities in the pesent study is also highly relevant as it pertains
to the concept of conversion therapy. Multiple trials in the litera-
ture have reported different conversion rates ranging from 3–72%
for patients who were unresectable at presentation but became
resectable after chemotherapy.10,21–24 Surprisingly, these variable
data were obtained in spite of using similar chemotherapy regi-
mens. However, a closer look reveals the lack of consensus in
defining unresectable disease. Some protocols did not include
specific criteria for resection of liver metastases, and attempts at a
curative resection were left to the surgeon’s discretion.21 Others
have relied on a single surgeon or a team of physicians to deter-
mine resectability.25,26 This observation may partially account for
the differences in the reported rates of success of different chemo-
therapy regimens, such that the effectiveness of downstaging
treatments will be heavily impacted by initial definitions of disease
resectability.27 The present study lends further support to this
hypothesis, particularly given the significant lack of agreement on
resectability observed for many test scenarios.
The results of the recent CELIM (Cetuximab and either
FOLFOX6 or FOLFIRI in neoadjuvant treatment of unresectable
colorectal liver metastases) trial support the conclusions reached
in the present study.28 In this trial, patients with colorectal liver
Figure 3 Comparison of the total number of scenarios resected and
adjunct modalities used per surgeon
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metastases initially deemed unresectable by local hepatic surgeons
were randomized to cetuximab plus FOLFOX6 or FOLFIRI. After
eight cycles of neoadjuvant chemotherapy, study participants were
reassessed for resectability by a multidisciplinary expert panel
blinded to clinical information. This trial found that 32% of
patients initially labelled as unresectable were thought to be
potentially resectable by the expert panel. After chemotherapy, the
proportion of potentially resectable patients increased to 60%. In
total, 34% of enrolled patients eventually underwent R0 liver
resection, whereas 46% of patients underwent R0/R1 and/or
radiofrequency ablation. The trial authors further highlighted the
significant inter-individual variability in opinions on resectability,
with 37–58% of patients considered resectable and 20–48% con-
sidered unresectable.
Limitations of the present study include the relatively small
sample size, the moderate number of test scenarios presented to
the surgeons, as well as the requirement for respondents to deter-
mine resectability on the basis of a single CT scan phase on a
standard definition computer screen. In addition, this work is
limited by its descriptive nature, and the homogeneity in the
surveyed population of hepatic surgeons, which limits the ability
to explain the observed variability of opinions among surgeons.
Conclusion
A significant lack of agreement was identified between surveyed
surgeons regarding the resectability of colorectal liver metastases.
Similarly, there was poor agreement on the use of adjunct modali-
ties to resection. These findings have important implications
concerning definitions of resectability and lend support to resec-
tability of individual patients being determined on the basis of
consensus conferences. Patients considered to be unresectable or
marginally resectable should be discussed in a multidisciplinary
tumour conference before being declined for operation. Tumour
boards should follow the best level of medical evidence and con-
sensus guidelines. Further research is required to guide future
efforts to standardize the concept of surgical resectability.
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